Donald Trump on Thursday sued the US treasury department and Internal Revenue Service for $10bn over the disclosure of his tax returns to the media in 2019 and 2020. In a complaint filed in Miami federal court, Trump, his adult sons, and his namesake company said the agencies failed to take “mandatory precautions” to prevent former IRS contractor Charles Littlejohn from leaking their tax returns t...
Donald Trump on Thursday sued the US treasury department and Internal Revenue Service for $10bn over the disclosure of his tax returns to the media in 2019 and 2020. In a complaint filed in Miami federal court, Trump, his adult sons, and his namesake company said the agencies failed to take “mandatory precautions” to prevent former IRS contractor Charles Littlejohn from leaking their tax returns to “leftist media outlets”, including the New York Times and ProPublica. The plaintiffs said they suffered “significant and irreparable harm” to their reputations and financial interests, and may seek punitive damages because the leaks were either willful or resulted from gross negligence. Thursday’s lawsuit puts Trump in the unusual position of suing government agencies that are part of the executive branch, which he leads. The IRS is part of the treasury department. Neither agency immediately responded to requests for comment after business hours. Scott Bessent, the treasury secretary and acting IRS commissioner, is not a defendant. Other plaintiffs include Donald Trump Jr, Eric Trump and the Trump Organization. Trump has filed many lawsuits in his personal capacity, often for large sums and as a result of reporting by various media, since winning a second White House term in 2024. He sued the New York Times and book publisher Penguin Random House for $15bn over articles and a book he said were intended to undermine his election prospects in 2024. Trump is separately seeking $10bn from the Wall Street Journal over an article discussing a birthday greeting for Jeffrey Epstein, and $10bn from the BBC over its editing of a speech preceding the January 6 storming of the US Capitol. Alejandro Brito, a Florida-based lawyer, filed or helped file all of these lawsuits, as well as the lawsuit against the IRS and treasury department. He did not immediately respond to a request for comment after business hours. In Thursday’s complaint, Trump and the other plaintiffs said the New York...
On Thursday, Nvidia Corp (NASDAQ:NVDA) CEO Jensen Huang said during a visit to Taiwan that surging AI demand is rapidly increasing the need for advanced memory. AI's Next Bottleneck Is Memory, Not Just Compute Huang said the future of artificial intelligence will be shaped as much by memory as by computing power, reported UDN, one of the leading media platforms in Taiwan. He noted that modern AI m...
On Thursday, Nvidia Corp (NASDAQ:NVDA) CEO Jensen Huang said during a visit to Taiwan that surging AI demand is rapidly increasing the need for advanced memory. AI's Next Bottleneck Is Memory, Not Just Compute Huang said the future of artificial intelligence will be shaped as much by memory as by computing power, reported UDN, one of the leading media platforms in Taiwan. He noted that modern AI models need to think, respond and reason at extremely high speeds, driving a sharp rise in memory capacity requirements across the industry. Nvidia Works With All Major HBM Suppliers He said Nvidia relies heavily on these partners to meet soaring demand this year. Taiwan Capacity Not Transferred To The US: Huang Huang rejected concerns that the U.S. has shifted about 40% of Taiwan's semiconductor manufacturing capacity stateside. Instead, he said global chip production should be viewed as expanding, with new capacity being added in the U.S., Europe and Japan while Taiwan remains a key manufacturing hub. TSMC Remains Nvidia's Irreplaceable Foundry Partner He said TSMC will need to significantly scale capacity over the next decade, with most production staying in Taiwan alongside overseas expansion. H200 China Approval Reports Are False Huang dismissed rumors circulating in mainland China that Nvidia's H200 AI chips have received regulatory approval, saying no orders have been placed and final clearance is still pending. If approval comes, he said, Nvidia is prepared to move quickly with partners to deliver products. Previously, it was reported that the clearance was granted during Huang's visit to China, where he's kicking off the company's annual events ahead of the Lunar New Year in mid-February. Nvidia's H200 Chip Sits At Center Of US-China Tensions Nvidia's H200 AI chip has become a flashpoint in U.S.-China tech tensions. While Washington has approved shipments, Beijing has yet to fully clear imports. This has fueled a gray market where servers equipped with eight H200 GP...
Key Points Intel's latest quarterly results make it clear the company isn't in a position to justify its expensive valuation. Another company is making notable progress in AI data center chips, primarily through its product-development efforts. This company is cheaper than Intel and is poised to deliver impressive revenue and earnings growth in the long run. 10 stocks we like better than Advanced ...
Key Points Intel's latest quarterly results make it clear the company isn't in a position to justify its expensive valuation. Another company is making notable progress in AI data center chips, primarily through its product-development efforts. This company is cheaper than Intel and is poised to deliver impressive revenue and earnings growth in the long run. 10 stocks we like better than Advanced Micro Devices › Intel(NASDAQ: INTC) has been one of the hottest stocks in the semiconductor space in the past six months. The share price is up an incredible 137% during this period, due to the company's turnaround efforts and investments by Nvidia, SoftBank, and the U.S. government, which have bolstered the company's balance sheet. However, Intel still has a lot of work to do before it can capitalize on the impressive growth opportunity in semiconductors. It wasn't surprising, then, to see Intel's stock crashing after releasing its latest quarterly report. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Let's see why that was the case and take a closer look at another semiconductor stock that's in a better position to make the most of the artificial intelligence (AI)-fueled growth in the semiconductor market. Intel's turnaround is going to take time Intel reported a 4% year-over-year drop in revenue in the fourth quarter of 2025. The company's data center and AI (DCAI) segment, however, reported slightly stronger year-over-year growth of 9%. Intel management pointed out on the latest earnings call that its DCAI revenue "would have been meaningfully higher if we had more supply." Management estimates that Intel's supply situation will start improving in the next quarter and continue to improve as the year progresses. As a result, there's a good chance the stock regains its momentum later in 2026, especially due to the healthy demand for its AI-focused of...
(RTTNews) - Kyivstar Group Ltd. (KYIV, KYIVW) announced the pricing of the public offering of 12.50 million common shares by VEON Amsterdam B.V., the principal shareholder of the Company, and certain other selling shareholders at a public offering price of $10.50 per share. The Company said it is not selling any common shares in the Offering. In connection with the Offering, the Selling Shareholde...
(RTTNews) - Kyivstar Group Ltd. (KYIV, KYIVW) announced the pricing of the public offering of 12.50 million common shares by VEON Amsterdam B.V., the principal shareholder of the Company, and certain other selling shareholders at a public offering price of $10.50 per share. The Company said it is not selling any common shares in the Offering. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on February 2, 2026, subject to customary closing conditions. Morgan Stanley, Barclays, Cantor and Rothschild & Co are acting as joint booking-running managers and as representatives of the underwriters for the proposed Offering. Benchmark, a StoneX Company, and Northland Capital Markets are acting as co-managers for the proposed Offering. KYIV closed at $12.05, up $0.04 or 0.33%. In overnight trading at 9:15:56 PM EST, the stock slipped to $11.99, reflecting a decline of $0.06 points or 0.50%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Microsoft Corporation (“Microsoft” or “the Company”) (NASDAQ: MSFT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose informatio...
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Microsoft Corporation (“Microsoft” or “the Company”) (NASDAQ: MSFT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Microsoft reported its financial results for Q2 2026 on January 28, 2026. Although many of the Company’s metrics were positive, Seeking Alpha reported on January 29, 2026, that Microsoft shares plunged almost 10% due to capacity restraints related to AI. According to the article, "’Approximately 45% of our commercial RPO balance is from OpenAI,’ said Microsoft Chief Financial Officer Amy Hood during Wednesday's earnings call. ‘The significant remaining balance grew 28% and reflects ongoing broad customer demand across the portfolio.’” If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Australian government’s main immigration detention contractor is playing a key role in Donald Trump’s hardline immigration crackdown and has attracted a string of complaints over its treatment of Immigration and Customs Enforcement (ICE) detainees. In recent years, the Albanese government has awarded lucrative immigration detention contracts to the local subsidiary of Management and Training C...
The Australian government’s main immigration detention contractor is playing a key role in Donald Trump’s hardline immigration crackdown and has attracted a string of complaints over its treatment of Immigration and Customs Enforcement (ICE) detainees. In recent years, the Albanese government has awarded lucrative immigration detention contracts to the local subsidiary of Management and Training Corporation, a major US private prison company, to operate offshore processing facilities on Nauru and Australia’s onshore detention network. The contracts were awarded despite serious concerns about MTC’s track record in the US, including allegations of “gross negligence” and “egregious” security failures, and allegations by the state of Mississippi that it had engaged in “a conspiracy scheme” of kickbacks, fraud and money laundering, paying bribes to state officials in exchange for contracts. Sign up: AU Breaking News email The company has since become closely involved in the Trump administration’s crackdown on immigrants. MTC is one of a handful of private prison operators running ICE detention facilities, holding thousands of detainees caught up in the agency’s mass arrest campaign. MTC holds detainees at the Bluebonnet and IAH Polk detention facilities in Texas, the Otero County Processing Center in New Mexico, and the Imperial Regional Detention Facility in California, near the Mexican border. The American Civil Liberties Union said that MTC has been the subject of a string of complaints about its treatment of ICE detainees, including allegations of assault at Bluebonnet, complaints of severe overcrowding at IAH Polk and Otero, the use of solitary confinement as a punitive measure at Otero and the death of a detainee at Imperial in September. Eunice Cho, senior counsel with the ACLU’s National Prison Project, said “the track record of private prison corporations like MTC, who uniquely profit from human suffering, including the recent crackdown on immigrant communities ...
Iman Rachman, chief executive officer of the Indonesia Stock Exchange, said he will step down following a two-day market rout sparked by MSCI Inc.’s warning of a possible downgrade. The resignation comes as investors remain on edge on whether regulatory efforts will be enough to satisfy the index compiler’s demands. The benchmark Jakarta Composite Index rebounded on Friday, rising as much as 2.2%.
Iman Rachman, chief executive officer of the Indonesia Stock Exchange, said he will step down following a two-day market rout sparked by MSCI Inc.’s warning of a possible downgrade. The resignation comes as investors remain on edge on whether regulatory efforts will be enough to satisfy the index compiler’s demands. The benchmark Jakarta Composite Index rebounded on Friday, rising as much as 2.2%.
'My Colon Literally Blew Up': Thousands Sue Over GLP-1 Weight Loss Drug Side Effects A growing wave of lawsuits is challenging the safety warnings accompanying blockbuster weight-loss drugs that have rapidly reshaped American medicine and culture, raising questions about whether patients were adequately informed of the risks tied to medications now used by tens of millions of people. Todd Engel is...
'My Colon Literally Blew Up': Thousands Sue Over GLP-1 Weight Loss Drug Side Effects A growing wave of lawsuits is challenging the safety warnings accompanying blockbuster weight-loss drugs that have rapidly reshaped American medicine and culture, raising questions about whether patients were adequately informed of the risks tied to medications now used by tens of millions of people. Todd Engel is one of several plaintiffs in a growing number of GLP-1 lawsuits (photo: Jack Gruber via USA Today) The plaintiffs’ stories vary widely, but share a common claim: that drugs known as GLP-1 receptor agonists - including Ozempic, Wegovy and Mounjaro - caused severe, life-altering injuries that were not sufficiently disclosed at the time they were prescribed. A Maryland truck driver says he suffered what doctors described as an "eye stroke," losing vision first in one eye and then the other. A Louisiana woman developed a serious neurological condition after weeks of vomiting and malnutrition. An Oklahoma real-estate agent alleges her colon ruptured without warning while she was driving her granddaughter home from a softball game. "My colon blew up. Literally blew up ," said JoHelen McClain, the Oklahoma plaintiff. "I was trying to slim down and feel healthy." All three are among more than 4,400 plaintiffs who have filed lawsuits since 2023 against the drugs’ manufacturers, Novo Nordisk and Eli Lilly , according to court filings. The cases are now consolidated into federal and state litigation expected to take years to resolve. Via USA Today The suits come amid explosive growth in the use of GLP-1 drugs. An estimated 12% of American adults - more than 31 million people - are currently using a GLP-1 medication , according to the nonpartisan health policy group KFF. Prescriptions rose from roughly one million in 2018 to about nine million in 2022, and usage doubled again between 2024 and 2025, Gallup data show. Originally developed to treat diabetes, the drugs mimic a hormone tha...